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 ABSTRACT 
 
The erythrocyte carries gases between the cells and the lungs, and has to distort to 
negotiate narrow splenic sinuses and capillaries. This distortion necessitates a 
high surface area to volume ratio that is maintained by the erythrocyte membrane 
skeleton, a network of proteins including spectrin and protein 4.1. The skeleton 
anchors the lipid bilayer through attachment to integral membrane proteins, 
notably the anion exchange protein, band 3. Abnormalities of the erythrocyte 
membrane proteins cause loss of cell elasticity and ultimately the erythrocytes 
become prematurely trapped in the spleen where they are phagocytosed, resulting 
in haemolytic anaemia.  
Three mutations causing band 3-deficient hereditary spherocytosis (HS), a 
haemolytic anaemia characterised by spherical erythrocytes, were located using 
restriction enzyme analysis and DNA sequencing. Proband A (Black) is 
heterozygous for band 3 Pinhal (R490H) and has mild clinical symptoms. Proband 
B and his mother (Caucasian) are heterozygous for band 3 Bicetre (R490C) and 
have severe anaemia requiring transfusions and splenectomy, respectively. These 
results confirm codon 490 as a hotspot for mutations and indicate the effect of 
different amino acid substitutions in the same position on clinical severity. 
Proband C (Black) is homozygous for a novel mutation (E508K) for which her 
parents are heterozygous. The proband is severely affected and transfusion- 
dependent whereas her father has moderate anaemia and her mother is 
asymptomatic. It is speculated that a secondary factor modulates their clinical 
symptoms. All of these mutations occur in a CpG dinucleotide, a common source 
of DNA mutations, and are located within the highly conserved exon 13, which 
encodes the third to fifth α-helices and the second extracellular loop of the 
transmembrane region of band 3. The mutations are likely to alter the 
conformation of band 3, impairing its insertion into the erythrocyte membrane. No 
causative mutations were located in another 12 band 3-deficient HS kindred using 
restriction enzymes and single strand conformation polymorphism analysis.  
Ten protein 4.1-deficient patients with hereditary elliptocytosis, a haemolytic 
anaemia characterised by elliptical erythrocytes, were also studied. Immunoblot 
analyses ruled out abnormally sized protein 4.1 and three known DNA mutations 
were excluded using restriction enzyme analysis. Further studies are required to 
elucidate the cause of the haemolytic anaemia in these kindred. 
This study advanced our knowledge of the molecular basis of HS in South African 
kindred and highlighted the susceptibility of CpG dinucleotides to mutations. 
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“Now what I want is, Facts. Teach these boys and girls nothing but Facts. 
Facts alone are wanted in life. Plant nothing else and root out all else… Stick 
to the Facts, Sir” 
Charles Dickens (1812-1870) in Hard Times (1854) 
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